|
|
Article: ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting.
- Article from:
- PR Newswire
- Article date:
- April 17, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Three Developmental Compounds Show Early Promise
MONTREAL, April 17 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced results of three compounds in preclinical studies for prostate and pancreatic cancer at the American Association for Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this week.
Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions as follows:
Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed significant antitumor activity in human prostate cancer both in vitro ...